Alnylam Pharmaceuticals this week said that the US Patent and Trademark Office has issued a notice of allowance for one of the company's patent applications related to lipid nanoparticles for systemic RNAi drug delivery.

Alnylam said that the patent application, No. 20100324120, is entitled “Lipid Formulation.” Alnylam said that it covers a variety of second-generation lipid nanoparticles including the so-called MC3 lipids used in the company's transthyretin-mediated amyloidosis drug ALN-TTR02 and its hypercholesterolemia treatment ALN-PCS.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.